Transient abrogation of immunosuppression in a patient with chronic mucocutaneous candidiasis following vaccination with Candida albicans
- PMID: 2952735
- DOI: 10.1016/s0163-4453(87)91977-3
Transient abrogation of immunosuppression in a patient with chronic mucocutaneous candidiasis following vaccination with Candida albicans
Abstract
A patient with long-standing chronic mucocutaneous candidiasis had reversed T helper/suppressor (TH/TS) cell ratios, hypergammaglobulinaemia E and serum inhibitors of lymphocyte transformation to mitogens and candida antigens. Following vaccination with whole heat-killed yeasts of Candida albicans, temporary clinical improvement coincided with the return of the TH/TS cell ratio to normal, reduction in concentration of IgE and reduced serum inhibitory activity to Concanavalin A and candida antigens. These changes were not permanent and 6 months after vaccination all indices had reverted to their pretreatment values. The production of antibody to a 47 kDa antigen of C. albicans has been shown to coincide with recovery from systemic disease. High concentrations of this antibody were demonstrated initially in the patient's serum and were unaffected by vaccination. If the 47 kDa antibody is protective, the results of this study suggest that separate immune responses may protect against mucocutaneous and systemic candidiasis and that defective immune responses against mucocutaneous disease need not imply lack of protection against systemic spread.
Similar articles
-
Suppressor T cells role in the unresponsiveness to Candida albicans in chronic mucocutaneous candidiasis.Boll Ist Sieroter Milan. 1985;64(2):126-30. Boll Ist Sieroter Milan. 1985. PMID: 3161525
-
An unusual combination of immunologic abnormalities in a patient with chronic mucocutaneous candidiasis.Ann Allergy. 1989 Aug;63(2):98-100, 147-8. Ann Allergy. 1989. PMID: 2669569 No abstract available.
-
Dual-antigen fusion protein vaccination induces protective immunity against Candida albicans infection in mice.Hum Vaccin Immunother. 2024 Dec 31;20(1):2406065. doi: 10.1080/21645515.2024.2406065. Epub 2024 Sep 26. Hum Vaccin Immunother. 2024. PMID: 39327639 Free PMC article.
-
Candida and AIDS: evidence for protective antibody.Lancet. 1988 Jul 30;2(8605):263-6. doi: 10.1016/s0140-6736(88)92547-0. Lancet. 1988. PMID: 2899245 Review.
-
Chronic mucocutaneous candidiasis.Eur J Clin Microbiol Infect Dis. 1989 May;8(5):448-56. doi: 10.1007/BF01964059. Eur J Clin Microbiol Infect Dis. 1989. PMID: 2502409 Review.
Cited by
-
Promising immunotherapeutic targets for treating candidiasis.Front Cell Infect Microbiol. 2024 Feb 9;14:1339501. doi: 10.3389/fcimb.2024.1339501. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38404288 Free PMC article. Review.
-
Cutaneous defenses against dermatophytes and yeasts.Clin Microbiol Rev. 1995 Jul;8(3):317-35. doi: 10.1128/CMR.8.3.317. Clin Microbiol Rev. 1995. PMID: 7553568 Free PMC article. Review.
-
Cell wall and secreted proteins of Candida albicans: identification, function, and expression.Microbiol Mol Biol Rev. 1998 Mar;62(1):130-80. doi: 10.1128/MMBR.62.1.130-180.1998. Microbiol Mol Biol Rev. 1998. PMID: 9529890 Free PMC article. Review.
-
Serologic response to cell wall mannoproteins and proteins of Candida albicans.Clin Microbiol Rev. 1998 Jan;11(1):121-41. doi: 10.1128/CMR.11.1.121. Clin Microbiol Rev. 1998. PMID: 9457431 Free PMC article. Review.
-
Early resistance of interleukin-10 knockout mice to acute systemic candidiasis.Infect Immun. 1999 Feb;67(2):670-4. doi: 10.1128/IAI.67.2.670-674.1999. Infect Immun. 1999. PMID: 9916075 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical